Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in homologous recombination-deficient BRCA-wildtype metastatic triple-negative breast and relapsed ovarian cancer
ACTRN12617000855325Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib in triple-negative breast cancer (TNBC) and ovarian cancer (2 cohorts), sponsored by University of Sydney. Primary endpoint: Objective tumor response rate. Started Sep 2018; status: completed.
02
Drugs
olaparib
03
Conditions
triple-negative breast cancer (TNBC)ovarian cancer
Beyond the preview
Go deeper on ACTRN12617000855325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000855325.